NCT00399893View on ClinicalTrials.gov

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

NATerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

September 30, 2010

Conditions
Prader-Willi Syndrome
Interventions
DRUG

Octreotide

Octreotide to be administered by subcutaneous injection three times daily

DRUG

Placebo

Placebo to be administered by subcutaneous injection three times daily while on study

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

collaborator

Novartis

INDUSTRY

lead

Duke University

OTHER